Basic Study
Copyright ©The Author(s) 2016.
World J Stem Cells. Mar 26, 2016; 8(3): 106-117
Published online Mar 26, 2016. doi: 10.4252/wjsc.v8.i3.106
Table 1 Effect of treatment with bone marrow derived mesenchymal stem cells on serum transforming growth factor beta-1 and monocyte chemoattractant protein-1 levels in Parkinson’s disease model
TGF-β1 (pg/mL)MCP-1 (pg/mL)
Ovariectomized control481.5 ± 7.588.1 ± 0.9
PD untreated691.2 ± 8.0a112.1 ± 1.9a
PD + BM-MSCs489.7 ± 13.0c89.6 ± 2.0c
Table 2 Effect of treatment with bone marrow derived mesenchymal stem cells on serum brain derived neurotrophic factor and brain dopamine levels as well as brain tyrosine hydroxylase and nestin genes expression level in Parkinson’s disease model
BDNF (pg/mL)DA (μg/g tissue)Relative expression of TH gene (TH/β-actin)Relative expression of nestin gene (nestin/β-actin)
Ovariectomized control3700 ± 26.4882 ± 20.31.19 ± 0.0041.30 ± 0.004
PD untreated2905 ± 72.9a599 ± 9.8a0.54 ± 0.009a0.67 ± 0.006a
PD + BM-MSCs3663 ± 17.8c874 ± 15.0c1.18 ± 0.004c1.29 ± 0.005c
Table 3 Effect of treatment with bone marrow derived mesenchymal stem cells on brain survivin expression in Parkinson’s disease model
Survivin (cell number)
Ovariectomized control288 ± 16.5
PD untreated271.5 ± 13.9
PD + BM-MSCs293.2 ± 15.9